GFAP and myeloid sarcoma: As neurofilament light chain is associated with new gadolinium‐enhancing lesions and relapses, while GFAP is not significantly affected by new relapse activity, GFAP may be a better marker of progressive MS biology and could help predict disability progression in the absence of acute inflammatory lesions.6, 9, 10, 11